Case Report
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. May 16, 2021; 9(14): 3418-3423
Published online May 16, 2021. doi: 10.12998/wjcc.v9.i14.3418
Change in neoadjuvant chemotherapy could alter the prognosis of patients with pancreatic adenocarcinoma: A case report
Alberto Meyer, Bárbara J Carvalho, Kayo AA Medeiros, Leonardo Z Pipek, Fernanda S Nascimento, Milena O Suzuki, João VT Munhoz, Leandro R Iuamoto, Luiz A Carneiro-D'Alburquerque, Wellington Andraus
Alberto Meyer, Luiz A Carneiro-D'Alburquerque, Wellington Andraus, Gastroenterologia, Hospital das Clínicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo 01426-010, Brazil
Bárbara J Carvalho, Kayo AA Medeiros, Leonardo Z Pipek, Fernanda S Nascimento, Milena O Suzuki, João VT Munhoz, Gastroenterologia, Faculdade de Medicina, da Universidade de São Paulo, São Paulo 05403-000, Brazil
Leandro R Iuamoto, Orthopaedics and Traumatology, Faculdade de Medicina, da Universidade de São Paulo, São Paulo 05403-000, Brazil
Author contributions: Meyer A, Carvalho BJ and Medeiros KAA were responsible for study design and writing; Pipek LZ, Nascimento FS, Suzuki MO and Munhoz JVT were responsible for data collections and data analysis; Meyer A, Carneiro-D'Alburquerque LA and Andraus W were involved in the study design and were responsible for scientific revision; All authors read and approved the final manuscript.
Informed consent statement: Written consent was obtained from each patient authorizing to publish their individual data or any accompanied figures in this manuscript.
Conflict-of-interest statement: The authors declare that they have no competing interests.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Alberto Meyer, FACS, MD, MSc, PhD, Assistant Professor, Gastroenterologia, Hospital das Clínicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, Av Dr Arnaldo 455, São Paulo 01426-010, Brazil. alberto.meyer@usp.br
Received: December 2, 2020
Peer-review started: December 2, 2020
First decision: December 31, 2020
Revised: December 31, 2020
Accepted: February 23, 2021
Article in press: February 23, 2021
Published online: May 16, 2021
Processing time: 147 Days and 10 Hours
Core Tip

Core Tip: Neoadjuvant treatment with folinic acid, 5-fluorouracil, irinotecan and oxaliplatine or gemcitabine plus nab-paclitaxel has become a standard of care for borderline or locally advanced pancreatic cancer and is increasingly considered even for up-front resectable disease.